About PharmaCare

B.C. PharmaCare is a government-funded drug plan. It helps British Columbians with the cost of eligible prescription drugs and specific medical supplies.

Details of Drug Reviewed

<table>
<thead>
<tr>
<th>Drug</th>
<th>umeclidinium bromide</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Brand Name</strong></td>
<td>Incruse™ Ellipta®</td>
</tr>
<tr>
<td><strong>Dosage Form(s)</strong></td>
<td>62.5 mcg dry powder for oral inhalation</td>
</tr>
<tr>
<td><strong>Manufacturer</strong></td>
<td>GlaxoSmithKline Inc.</td>
</tr>
</tbody>
</table>

**Submission Review**

- **Use Reviewed**: Chronic obstructive pulmonary disease (COPD)
- **Common Drug Review (CDR)**: Yes. CDR recommended: **List with criteria**. Visit the CDR website for more details: [www.cadth.ca/node/88649](http://www.cadth.ca/node/88649).
- **Provincial Review**: DBC now screens drug submissions under review by the CDR to determine whether or not a full DBC review is necessary, based on past DBC reviews, recommendations, and existing PharmaCare coverage. If a full DBC review is determined to not be required, the Ministry’s drug coverage decision will be based on the Canadian Drug Expert Committee (CDEC) recommendation and an internal review only. The DBC screened umeclidinium on June 1, 2015 and advised that because umeclidinium is similar to other drugs previously reviewed by the Council for the treatment of COPD, the Ministry may accept the CDEC’s recommendation for umeclidinium.

**Drug Coverage Decision**

- **Limited Coverage Benefit**. Access the umeclidinium criteria from: [www.gov.bc.ca/pharmacarespecialauthority](http://www.gov.bc.ca/pharmacarespecialauthority).

<table>
<thead>
<tr>
<th>Date</th>
<th>March 15, 2016</th>
</tr>
</thead>
</table>
| **Reasons**  | The Ministry reviewed clinical evidence and pharmacoeconomic reports prepared by the CDR, the Final CDEC Recommendation, and patient input from one patient, and one patient group collected through Your Voice.  
  - The available clinical evidence demonstrated that treatment with umeclidinium improved lung function in patients with moderate to severe COPD.  
  - Umeclidinium demonstrated advantage over placebo with respect to efficacy and health-related quality of life.  
  - Based on economic considerations and the submitted product price, the drug offers value for money compared to existing drugs for the treatment of COPD.  |
| **Other Information** | None |
The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent group called the Drug Benefit Council (DBC) gives advice to the Ministry. The DBC looks at:
- advice from a national group called the Common Drug Review
- whether the drug is safe and effective
- whether it is a good value for the people of B.C.
- the ethics of covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes a decision based on many factors, including:
- advice from the DBC
- drugs used to treat similar medical conditions that B.C. PharmaCare already covers
- the overall cost of covering the drug

Visit the B.C. Drug Review Process and PharmaCare program for more information.

This document is intended for information only.
It does not take the place of advice from a physician or other qualified health care provider.